Hilleman Laboratories developed affordable Haemophilus influenzae type b (Hib) vaccine

The new vaccine was also proved as 4 to 10 times more potent when compared to the existing licensed vaccines.

Created On: Jun 30, 2015 10:00 ISTModified On: Jun 30, 2015 12:56 IST

Hilleman Laboratories (HL), a global vaccine research and development organisation on 24 June 2015 announced the success of a preclinical trial conducted for Haemophilus influenzae type b (Hib) vaccine.

The research was published in the journal Vaccine.

The new vaccine formulation is expected to fill the immunization gap in the country as it is more cost effective and immunogenic compared to existing available vaccines.

The new vaccine was proved as 4 to 10 times more potent when compared to the existing licensed vaccines.

The Hib conjugate vaccine, which plays a vital role in national immunization programmes and also forms a main part of several mono-or multivalent vaccines for children, is the costliest component.

Hence, low cost of Hib makes a spectrum of vaccines more affordable and accessible even to the poor people in the country.

Hib is a deadly bacterium. It causes severe diseases like pneumonia and meningitis that are the leading causes of child deaths in India accounting for nearly 20 percent of the global deaths among children.

New Delhi based Hilleman Laboratories operates on a not-for-profit principle. It was formed as a partnership between global pharmaceutical organisation Merck & Co and the Wellcome Trust.

The UK based Wellcome Trust is a global charitable foundation dedicated to human and animal health. In the field of medical research, it is the world's second-largest private funder after the Bill & Melinda Gates Foundation.

Now get latest Current Affairs on mobile, Download # 1 Current Affairs App

Take Weekly Tests on app for exam prep and compete with others. Download Current Affairs and GK app

एग्जाम की तैयारी के लिए ऐप पर वीकली टेस्ट लें और दूसरों के साथ प्रतिस्पर्धा करें। डाउनलोड करें करेंट अफेयर्स ऐप

AndroidIOS

Related Stories

Comment (0)

Post Comment

3 + 2 =
Post
Disclaimer: Comments will be moderated by Jagranjosh editorial team. Comments that are abusive, personal, incendiary or irrelevant will not be published. Please use a genuine email ID and provide your name, to avoid rejection.

    Monthly Current Affairs PDF

    • Current Affairs PDF November 2021
    • Current Affairs PDF October 2021
    • Current Affairs PDF September 2021
    • Current Affairs PDF August 2021
    • Current Affairs PDF July 2021
    • Current Affairs PDF June 2021
    View all

    Monthly Current Affairs Quiz PDF

    • Current Affairs Quiz PDF November 2021
    • Current Affairs Quiz PDF October 2021
    • Current Affairs Quiz PDF September 2021
    • Current Affairs Quiz PDF August 2021
    • Current Affairs Quiz PDF July 2021
    • Current Affairs Quiz PDF June 2021
    View all